September 5, 2024
Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations
Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan
European Court Suspends EC’s Decision to Revoke Ocaliva’s Marketing Authorization
Ocaliva, European Court, EC decision, marketing authorization, primary biliary cholangitis, PBC, Advanz Pharma
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
BioMarin Undergoes Strategic Restructuring Amid Slow Roctavian Sales and Staff Layoffs
BioMarin, restructuring, Roctavian, staff layoffs, corporate strategy, hemophilia gene therapy
Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition
Astellas, Takeda, ADHD drug, Vyvanse, generic competition, facility closure
Novartis Expands Radioligand Therapy Manufacturing with $200M Investment in Two US Sites
Novartis, radioligand therapy, manufacturing expansion, $200M investment, California, Indianapolis
IN8bio Shifts Focus to Leukemia Cell Therapy, Halts Glioblastoma Trial and Reduces Workforce
IN8bio, glioblastoma trial halt, workforce reduction, leukemia cell therapy, gamma-delta T cell therapies
Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version
Moderna, Mpox vaccine, Preclinical study, Superior efficacy, Approved version
Astellas Gene Therapies to Close South San Francisco Manufacturing Facility
Astellas Gene Therapies, South San Francisco, manufacturing facility closure, gene therapy, biotech layoffs
ArsenalBio Secures $325M Funding to Advance Programmable CAR-T Therapies
ArsenalBio, CAR-T therapies, biotech funding, programmable cell therapies, solid tumors, Regeneron, BMS